Targets › SNARE
11 programs from 10 companies in 12 trials: 5 Phase 2, 4 Phase 3, 2 Phase 4, 1 Phase 1; Genitourinary, Other, Psychiatry; next expected readout Dec 2026.
Open in Phaseline: the race on SNARE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Boston Medical Center | prabotulinumtoxinA-xvfs Botulinum toxin serotype A; cleaves SNARE proteins to inhibit acetylcholine release at the | SNARE | Phase 4 | Neck Muscle Issue | Mar 2027 |
| David M. Simpson | Abobotulinum toxin A (Dysport) Botulinum toxin type A; cleaves SNARE proteins to inhibit acetylcholine release at neuromu | SNARE | Phase 4 | Tremor, Limb | – |
| Region Stockholm | Botulinum toxin A (5U/0.1 ml) Neuromuscular blocking agent; cleaves SNARE proteins to inhibit acetylcholine release | SNARE | Phase 3 | Temporomandibular Disorder | Dec 2026 |
| University Hospital, Rouen | intra-rectal botulinum toxin injections SNARE complex inhibitor; blocks acetylcholine release at neuromuscular junction | SNARE | Phase 3 | Fecal Incontinence | Jun 2027 |
| Assistance Publique - Hôpitaux de Paris | BTA (XEOMIN®) Botulinum toxin A - reversible neuromuscular blockade inducing flaccid paralysis of latera | SNARE | Phase 3 | Incisional Hernia | Aug 2028 |
| Copenhagen University Hospital, Rigshospitalet | Incobotulinumtoxin-A Botulinum toxin A that cleaves SNARE proteins to inhibit acetylcholine release at the neur | SNARE | Phase 2 | Diabetic Neuropathy, Painful | May 2027 |
| Vensica Therapeutics | NT 201 200U Botulinum toxin type A | SNARE | Phase 2 | Overactive Bladder (OAB) | Sep 2027 |
| Vensica Therapeutics | NT 201 300U Botulinum toxin type A | SNARE | Phase 2 | Overactive Bladder (OAB) | Sep 2027 |
| Abdallah Mohamed Abdallah Mohamed Elgendy | 25 units Botulinum Toxin-A Botulinum toxin serotype A; cleaves SNARE complex proteins to block acetylcholine release | SNARE | Phase 2 | Premature Ejaculation | – |
| Eirion Therapeutics | AI-09 Ready Use Injectable Botulinum Toxin Botulinum toxin type A - cleaves SNARE proteins, blocking acetylcholine release at the neu | SNARE | Phase 2 | Glabellar Lines | – |
| University of Miami | Botulinum neurotoxin SNARE complex inhibitor; presynaptic acetylcholine release inhibitor | SNARE | Phase 1 | Pelvic Floor Disorders | Mar 2027 |
Overactive Bladder (OAB) (2) Temporomandibular Disorder (2) Fecal Incontinence (1) Premature Ejaculation (1) Tremor, Limb (1) Diabetic Neuropathy, Painful (1) Pelvic Floor Disorders (1) Incisional Hernia (1) Neck Muscle Issue (1) Glabellar Lines (1)
protein or peptide (7), small molecule (2), other (2)
Vensica Therapeutics (2) University Hospital, Rouen (1) Abdallah Mohamed Abdallah Mohamed Elgendy (1) David M. Simpson (1) Copenhagen University Hospital, Rigshospitalet (1) University of Miami (1) Assistance Publique - Hôpitaux de Paris (1) Boston Medical Center (1) Region Stockholm (1) Eirion Therapeutics (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.